News

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Visa, Home Depot, and Abbott Laboratories are blue chip stocks that can provide your portfolio with a good mix of safety, stability, and dividend income over the long term.

Abbott Laboratories (NYSE:ABT) is one of the best healthcare stocks to buy with highest upside potential. Abbott Laboratories (NYSE:ABT) announced on May 27 that it has secured CE Mark for the world’s first dual glucose‑ketone sensing technology for people with diabetes. The systems are branded as Libre Duo and Libre Duo 10 Day, and are specifically […]

Over the long term, the IHI ETF looks like a good turnaround story.

If you are wondering whether Abbott Laboratories at around US$91.07 is a bargain or a value trap, you will want to look closely at what the current valuation is really telling you. The stock has risen 3.7% over the past week and 8.0% over the past month, yet it remains down 26.7% year to date and down 30.3% over the last year, which raises fair questions about how sentiment and risk perception have shifted. Recent headlines have focused on Abbott Laboratories as a large healthcare player,...

Abbott Laboratories (NYSE:ABT) is one of the Best Blue Chip Stocks Under $100 to Buy Now. On May 27, analyst David Roman from Goldman Sachs maintained a “Buy” rating on the company’s stock and reduced the price objective to $113.00 from $121.00. The analyst’s rating is supported by several factors that highlight improvements in fundamentals and an attractive […]

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

Insulet Corporation (NASDAQ:PODD) is one of the oversold stocks to buy right now. On June 3, Insulet launched significant enhancements to its Omnipod 5 Automated Insulin Delivery/AID System in the US, featuring a new 100 mg/dL Target Glucose option. This update allows for greater personalization and improved glycemic control, enabling users to increase their time […]

About 50 million Americans aren’t getting screened for colon cancer at a time when colon-cancer rates are rising.

In early June 2026, Insulet began rolling out FDA-cleared algorithm enhancements to its Omnipod 5 Automated Insulin Delivery System in the U.S., adding a 100 mg/dL target option and new compatibility with Abbott’s Libre 3 Plus sensor via over-the-air updates and newly shipped Pods. This combination of tighter glucose personalization, improved automated mode performance, and broader sensor choice strengthens Omnipod 5’s appeal for both patients and clinicians even as the company manages...

ABT wins the CE Mark for Libre Duo sensors that track glucose and ketones every minute, aiming to spot DKA risks earlier and reduce routine testing.

Abbott Laboratories (NYSE:ABT) was among the stocks Jim Cramer talked about as he discussed the recent rally in several AI-related stocks. Cramer mentioned the company during the episode and stated: Now, let’s talk about some legendary growth companies and what’s happened to their stocks. Consider three really high-quality MedTech companies: Abbott Labs, Boston Scientific, and […]

Abbott Laboratories (ABT) is back in focus after it expanded its collaboration with MiniMed on dual glucose ketone sensors and received fresh support from the American Cancer Society for its Cologuard colorectal cancer screening tests. See our latest analysis for Abbott Laboratories. Even with supportive news on diabetes sensors and cancer screening, Abbott’s recent share price return tells a different story, with the stock down about 22% over 90 days and its 1-year total shareholder return...

QDEL's Q1 results show how a milder respiratory season can pressure revenue, margins and cash flow despite stable testing market share.

The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.

In its first earnings call, the newly independent diabetes tech firm said it was transforming its product portfolio, with plans that include a patch pump and an algorithm that doesn’t require meal announcements.

Abbott Laboratories currently has no change to its price target, with recent updates leaving existing estimates in place. In this article, you will see what this stable price target may mean for your view on the stock today and how to keep track of shifts as the analyst narrative evolves. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find new ways to value Abbott Laboratories. Do your thoughts align with the Bull or Bear Analysts? Perhaps you...

The Mairs & Power, an investment firm, released the first-quarter 2026 investor letter for the “Mairs & Power Balanced Fund.” A copy of the letter can be downloaded here. The fund returned -1.77% in the first quarter of 2026, outperforming its benchmark composite index decline of -2.68% as strong stock selection and exposure to Utilities […]

Intuitive Surgical is building an AI-driven surgical ecosystem, using da Vinci 5 data and connected workflows to deepen its robotic surgery moat.

Don't wait too long to buy the dip on these stocks.

Boston Scientific Corporation (NYSE:BSX) was among the stocks Jim Cramer was focused on, as he discussed Mad Money’s latest game plan for the week. An Investing Club member sought Cramer’s advice about choosing the best medical equipment maker out of the three: Abbott Labs, Boston Scientific, and Medtronic. He replied: Boston Scientific had a very […]

ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.

Earlier this week, the American Cancer Society updated its colorectal cancer screening guidelines, reaffirming Abbott’s Cologuard and Cologuard Plus as preferred noninvasive options for average-risk adults aged 45 and older, to be used every three years. The guidelines, combined with real-world data showing Cologuard tests drove an estimated very large share of CRC screening participation growth between 2018 and 2021, underscore how Abbott’s screening platform and patient navigation...

Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Investing.com -- Wolfe Research downgraded Boston Scientific to Peer Perform in a note on Friday, declaring the end of a multiyear bullish thesis on the medical device company after its two key growth engines (pulsed field ablation and the Watchman left atrial appendage closure device) stalled sharply in the first half of 2026.

Abbott Laboratories has trailed the Dow Jones Industrial Average over the past year, but analysts remain highly optimistic about the company's long-term growth prospects.

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

The Libre Duo systems are the first glucose-ketone monitors to reach the diabetes market.

Abbott Laboratories (NYSE:ABT) is one of the best medical technology stocks to buy right now. On April 28, Abbott Laboratories (NYSE:ABT) announced that the US Food and Drug Administration (FDA) and European regulators granted clearance and CE Mark approval, respectively, for its next-generation Ultreon 3.0 software. The software is an AI-powered coronary imaging platform designed […]